Mansoor Saleh, MD, returned to the University of Alabama at Birmingham (UAB) as full-time faculty on January 1, 2015 as Director of UAB’s Phase I Clinical Trials Program and Medical Director for the UAB Clinical Trials Office.
Dr. Saleh was born in Zanzibar, received his early education in Tanzania and Kenya, and his medical training at the University of Heidelberg in Germany. He conducted his graduate research work at the Max Planck Institute for Medical Research in Heidelberg before moving to the United States for his post graduate training.
He received his Internal Medicine residency training at the Henry Ford Hospital in Detroit, Michigan, and his fellowship in Hematology-Oncology and translational research at the University of Alabama at Birmingham Comprehensive Cancer Center under the mentorship of Dr. Albert F. LoBuglio. His area of clinical focus and translational research has been targeted therapy of cancer with a focus on monoclonal antibody therapy, and more recently on small molecules and immunotherapy. Dr. Saleh was a member of the UAB Comprehensive Cancer Center team, under Dr. LoBuglio, that conducted and published the first-in-human experience of murine, chimeric and humanized monoclonal antibodies. His clinical focus also included the study and treatment of immune thrombocytopenia, and laboratory work dedicated at generating anti-platelet antibodies from splenic B-cell derived from ITP patients. As part of his translational research career he developed an anti-idiotypic monoclonal antibody that mimics the GD2 antigen, a discovery for which he holds a patent. During his time at UAB, he developed expertise in clinical trials and clinical investigation and was the Associate Director for Clinical Research at the UAB Comprehensive Cancer Center.
He was a full-time faculty member at UAB from 1988-1999 rising to the rank of Professor based on an outstanding record of clinical research and service. In 1999, he joined Georgia Cancer Specialists in Atlanta where he served as Director for Research Development and established one of the few Phase I programs in private practice within the United States. While in private practice, he continued to devote 20% of his time to UAB, serving as Chairman of the Clinical Trials Review Committee and Associate Director for the Clinical Trials Network.
Since his return to UAB, he has assumed the leadership of the newly established Phase I Program that provides a centralized operation for the conduct of all first-in-human studies at the UAB Comprehensive Cancer Center. This is one of a few such Phase I Programs in the country and has achieve a time-to-trial-activation (CDA to SIV) of just over 100 days. The Phase I Program includes faculty that conduct first in-human-studies across all of the major disease areas in hematology and oncology and a staff of twenty who oversee the entire clinical, administrative, regulatory and financial operation of the program.
Dr. Saleh is the recipient of numerous awards and honors. He has published close to 100 peer reviewed publications and thirteen book chapters. His focus has been in the area of targeted therapy of cancer and translational research. He is internationally known for his work with monoclonal antibodies in the treatment of cancer as well as the treatment of Idiopathic Thrombocytopenic Purpura (ITP) using novel agents. He is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Association of Cancer Research (AACR) and the American Medical Association (AMA).